Please assess the completion status of the following clinical trial:

Trial Title: Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented previously untreated, Mucinous glycoprotein 1 (MUC1)-expressing, slowly progressive asymptomatic multiple myeloma with an increasing M-protein concentration displayed on two occasions separated by an interval of at least 4 weeks within the last 18 months, or~* Documented MUC1-expressing stage II or III multiple myeloma with a treatment-free interval of at least 3 months following prior anti-tumor therapy, and fulfilling criteria for having a stable response/plateau phase~* Signed written informed consent~* MUC1-expressing myeloma cells in the bone marrow~* Greater than or equal to (\>=) 18 years of age~* Life expectancy of at least 6 months~* Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to (\<=) 1 at study entry~* Effective contraception for both male and female subjects, if the possibility of conception exists~* A platelet count \>=100 x 10\^9/Liter, white blood cells \>=2.5 x 10\^9/Liter, and hemoglobin \>=90 gram per liter (g/L)~* Total bilirubin \<= 1.5 x upper reference range~* Aspartate aminotransferase (AST) \<= 2.5 x upper reference range~* Serum creatinine \<= 2 x upper reference~Exclusion Criteria:~Pre-Therapies:~* Previous exposure to MUC1 targeting therapy~* Radiotherapy or any investigational drug in the 30 days before the start of treatment in this study~* Receipt of immunotherapy (Example: interferons, tumor necrosis factor \[TNF\], interleukins, or biological response modifiers \[granulocyte macrophage colony stimulating factor {GM-CSF}, granulocyte colony stimulating factor {G-CSF}, macrophage-colony stimulating factor {M-CSF}\], monoclonal antibodies) within 4 weeks (28 days) prior to randomization~* Any preexisting medical condition requiring chronic oral or intravenous steroid or immunosuppressive therapy except for maintenance doses of prednisone of \<=10 milligram per day (mg/day)~Medical Conditions:~* Autoimmune disease that in the opinion of the investigator could compromise the safety of the subject in this study~* Hereditary or congenital immunodeficiencies~* Known hypersensitivity reaction to any of the components of study treatments~* Clinically significant cardiac disease, Example: New York Heart Association (NYHA) classes III-IV; unstable angina, uncontrolled arrhythmia or uncontrolled hypertension, myocardial infarction in the previous 6 months~* Other previous malignancies within 5 years, with exception of a history of a previous basal cell carcinoma of the skin, carcinoma in situ of uterine cervix, gastrointestinal intramucosal carcinoma~* Known Hepatitis B and/or C~* Splenectomy~Standard Safety:~* Known alcohol or drug abuse~* Medical or psychological conditions that would not permit the subject to complete the study or sign informed consent~* Significant disease which, in the investigator's opinion, would exclude the subject from the study~* Pregnant or breast-feeding women, women of childbearing potential, unless using effective contraception as determined by the investigator. Subjects whom the investigator considers may be at risk of pregnancy will have a pregnancy test performed per institutional standard~* Participation in another clinical study within the past 30 days~* Legal incapacity or limited legal capacity~* Concurrent treatment with a non-permitted drug~* Any other reason that, in the opinion of the investigator, precludes the subject from participating in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tecemotide (L-BLP25) plus single low dose cyclophosphamide (Type: EXPERIMENTAL): None
- Tecemotide (L-BLP25) plus multiple low dose cyclophosphamide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete